1589503-30-9

1589503-30-9 structure

Name: Afasevikumab
Chemical Name: Afasevikumab
CAS Number: 1589503-30-9
Molecular Formula: C₁₃H₁₅NO₆
Molecular Weight: 281.26
Catalog: Signaling Pathways Immunology/Inflammation Interleukin Related
Create Date: 2023-01-28 11:40:04
Modify Date: 2026-07-02 11:01:04
Afasevikumab (RG 7624; RO 5553110; NI-1401) is a fully human monoclonal IgG1κ antibody neutralizing both IL-17A and IL-17F. Afasevikumab has anti-inflammatory activities[1].

Name	Afasevikumab

Description	Afasevikumab (RG 7624; RO 5553110; NI-1401) is a fully human monoclonal IgG1κ antibody neutralizing both IL-17A and IL-17F. Afasevikumab has anti-inflammatory activities[1].
Related Catalog	Signaling Pathways >> Immunology/Inflammation >> Interleukin Related Research Areas >> Inflammation/Immunology
In Vitro	Afasevikumab 由 N 末端 IL-17F 特异性部分、结合 IL-17A 和 IL-17F 的 a-C 末端部分以及结合人血清白蛋白的中心部分组成[1]。
References	[1]. Andrea Chiricozzi, et al. Emerging treatment options for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis: evaluating bimekizumab and its therapeutic potential. Psoriasis (Auckl). 2019 May 24;9:29-35.